BridgeMD
New treatment option for Parkinson Disease
Official title Rehabilitation of Airway Protection in Parkinson's Disease
ClinicalTrials.gov ID: NCT05700825
What this study is testing
- What it's testing
- Airway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address these critical deficits.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 90
You may be able to join if
- Diagnosed with PD (Hoehn and Yahr Stages II-IV)126,127 confirmed by a Movement Disorders fellowship trained neurologist having reviewed the video...
- airway protective deficits as defined as a minimum of penetration of thin liquids (penetration-aspiration score\>3) as determined by instrumental...
- not actively receiving exercise-based swallowing therapy
- between the ages of 50 and 90.
You likely can't join if
- Other neurological disorders (e.g., multiple sclerosis, stroke, brain tumor, etc.)
- history of head and neck cancer
- history of breathing disorders or diseases (e.g., COPD)
- history of smoking in the last five years
- uncontrolled hypertension
- difficulty complying due to neuropsychological dysfunction (i.e., severe depression with \>28 on the Beck Depression Index (BDI-II), dementia with...
See the full eligibility criteria
- Diagnosed with PD (Hoehn and Yahr Stages II-IV)126,127 confirmed by a Movement Disorders fellowship trained neurologist having reviewed the video recorded Movement Disorders Society-Unified Parkinson's Disease Rating...
- airway protective deficits as defined as a minimum of penetration of thin liquids (penetration-aspiration score\>3) as determined by instrumental swallowing assessment and/or dystussia as determined by voluntary cough...
- not actively receiving exercise-based swallowing therapy
- between the ages of 50 and 90.
- Other neurological disorders (e.g., multiple sclerosis, stroke, brain tumor, etc.)
- history of head and neck cancer
- history of breathing disorders or diseases (e.g., COPD)
- history of smoking in the last five years
- uncontrolled hypertension
- difficulty complying due to neuropsychological dysfunction (i.e., severe depression with \>28 on the Beck Depression Index (BDI-II), dementia with \<19 on the Montreal Cognitive Assessment (MoCA))
- allergy to capsaicin or barium
- further than 1.5 hours (door to door) distance from either Teachers College, Columbia University or Purdue University.
The study team makes the final eligibility decision.
Where it's taking place
- West Lafayette, Indiana, United States
- New York, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include West Lafayette, Indiana, United States; New York, New York, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.